1
|
Burk AC, Apostolova P. Metabolic instruction of the graft-versus-leukemia immunity. Front Immunol 2024; 15:1347492. [PMID: 38500877 PMCID: PMC10944922 DOI: 10.3389/fimmu.2024.1347492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 02/05/2024] [Indexed: 03/20/2024] Open
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed to cure hematological malignancies, such as acute myeloid leukemia (AML), through the graft-versus-leukemia (GVL) effect. In this immunological process, donor immune cells eliminate residual cancer cells in the patient and exert tumor control through immunosurveillance. However, GVL failure and subsequent leukemia relapse are frequent and associated with a dismal prognosis. A better understanding of the mechanisms underlying AML immune evasion is essential for developing novel therapeutic strategies to boost the GVL effect. Cellular metabolism has emerged as an essential regulator of survival and cell fate for both cancer and immune cells. Leukemia and T cells utilize specific metabolic programs, including the orchestrated use of glucose, amino acids, and fatty acids, to support their growth and function. Besides regulating cell-intrinsic processes, metabolism shapes the extracellular environment and plays an important role in cell-cell communication. This review focuses on recent advances in the understanding of how metabolism might affect the anti-leukemia immune response. First, we provide a general overview of the mechanisms of immune escape after allo-HCT and an introduction to leukemia and T cell metabolism. Further, we discuss how leukemia and myeloid cell metabolism contribute to an altered microenvironment that impairs T cell function. Next, we review the literature linking metabolic processes in AML cells with their inhibitory checkpoint ligand expression. Finally, we focus on recent findings concerning the role of systemic metabolism in sustained GVL efficacy. While the majority of evidence in the field still stems from basic and preclinical studies, we discuss translational findings and propose further avenues for bridging the gap between bench and bedside.
Collapse
Affiliation(s)
- Ann-Cathrin Burk
- German Cancer Consortium (DKTK), partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany
- Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Petya Apostolova
- Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
- Division of Hematology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|
2
|
Dobrovolskaite A, Madan M, Pandey V, Altomare DA, Phanstiel O. The discovery of indolone GW5074 during a comprehensive search for non-polyamine-based polyamine transport inhibitors. Int J Biochem Cell Biol 2021; 138:106038. [PMID: 34252566 DOI: 10.1016/j.biocel.2021.106038] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 06/28/2021] [Accepted: 07/05/2021] [Indexed: 01/15/2023]
Abstract
The native polyamines putrescine, spermidine, and spermine are essential for cell development and proliferation. Polyamine levels are often increased in cancer tissues and polyamine depletion is a validated anticancer strategy. Cancer cell growth can be inhibited by the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO), which inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthesis pathway. Unfortunately, cells treated with DFMO often replenish their polyamine pools by importing polyamines from their environment. Several polyamine-based molecules have been developed to work as polyamine transport inhibitors (PTIs) and have been successfully used in combination with DFMO in several cancer models. Here, we present the first comprehensive search for potential non-polyamine based PTIs that work in human pancreatic cancer cells in vitro. After identifying and testing five different categories of compounds, we have identified the c-RAF inhibitor, GW5074, as a novel non-polyamine based PTI. GW5074 inhibited the uptake of all three native polyamines and a fluorescent-polyamine probe into human pancreatic cancer cells. GW5074 significantly reduced pancreatic cancer cell growth in vitro when treated in combination with DFMO and a rescuing dose of spermidine. Moreover, GW5074 alone reduced tumor growth when tested in a murine pancreatic cancer mouse model in vivo. In summary, GW5074 is a novel non-polyamine-based PTI that potentiates the anticancer activity of DFMO in pancreatic cancers.
Collapse
Affiliation(s)
- Aiste Dobrovolskaite
- Department of Medical Education, College of Medicine, University of Central Florida, Orlando, 32827, United States
| | - Meenu Madan
- Department of Medical Education, College of Medicine, University of Central Florida, Orlando, 32827, United States
| | - Veethika Pandey
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, 32827, United States
| | - Deborah A Altomare
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, 32827, United States
| | - Otto Phanstiel
- Department of Medical Education, College of Medicine, University of Central Florida, Orlando, 32827, United States.
| |
Collapse
|
3
|
Alliot J, Theodorou I, Ducongé F, Gravel E, Doris E. Polyamine transport system-targeted nanometric micelles assembled from epipodophyllotoxin-amphiphiles. Chem Commun (Camb) 2019; 55:14968-14971. [DOI: 10.1039/c9cc07883e] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Micelle-forming amphiphilic drug conjugates were synthesized starting from a biologically active epipodophyllotoxin derivative which was covalently inserted in between a hydrophilic targeting spermine unit, and a hydrophobic stearyl chain.
Collapse
Affiliation(s)
- Julien Alliot
- Service de Chimie Bioorganique et de Marquage (SCBM)
- CEA
- Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Ioanna Theodorou
- Molecular Imaging Research Center (MIRCen)
- CEA
- Université Paris-Saclay
- URA2210
- 92265 Fontenay-aux-Roses
| | - Frédéric Ducongé
- Molecular Imaging Research Center (MIRCen)
- CEA
- Université Paris-Saclay
- URA2210
- 92265 Fontenay-aux-Roses
| | - Edmond Gravel
- Service de Chimie Bioorganique et de Marquage (SCBM)
- CEA
- Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Eric Doris
- Service de Chimie Bioorganique et de Marquage (SCBM)
- CEA
- Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| |
Collapse
|
4
|
Abstract
This chapter provides an overview of how the polyamine pathway has been exploited as a target for the treatment and prevention of multiple forms of cancer, since this pathway is disrupted in all cancers. It is divided into three main sections. The first explores how the polyamine pathway has been targeted for chemotherapy, starting from the first drug to target it, difluoromethylornithine (DFMO) to the large variety of polyamine analogues that have been synthesised and tested throughout the years with all their potentials and pitfalls. The second section focuses on the use of polyamines as vectors for drug delivery. Knowing that the polyamine transport system is upregulated in cancers and that polyamines naturally bind to DNA, a range of polyamine analogues and polyamine-like structures have been synthesised to target epigenetic regulators, with encouraging results. Furthermore, the use of polyamines as transport vectors to introduce toxic/bioactive/fluorescent agents more selectively to the intended target in cancer cells is discussed. The last section concentrates on chemoprevention, where the different strategies that have been undertaken to interfere with polyamine metabolism and function for antiproliferative intervention are outlined and discussed.
Collapse
Affiliation(s)
- Elisabetta Damiani
- School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.,Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Heather M Wallace
- School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
| |
Collapse
|
5
|
Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα. Bioorg Med Chem Lett 2017; 27:4687-4693. [PMID: 28919339 DOI: 10.1016/j.bmcl.2017.09.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 08/31/2017] [Accepted: 09/04/2017] [Indexed: 01/03/2023]
Abstract
It has been proposed that xanthone derivatives with anticancer potential act as topoisomerase II inhibitors because they interfere with the ability of the enzyme to bind its ATP cofactor. In order to further characterize xanthone mechanism and generate compounds with potential as anticancer drugs, we synthesized a series of derivatives in which position 3 was substituted with different polyamine chains. As determined by DNA relaxation and decatenation assays, the resulting compounds are potent topoisomerase IIα inhibitors. Although xanthone derivatives inhibit topoisomerase IIα-catalyzed ATP hydrolysis, mechanistic studies indicate that they do not act at the ATPase site. Rather, they appear to function by blocking the ability of DNA to stimulate ATP hydrolysis. On the basis of activity, competition, and modeling studies, we propose that xanthones interact with the DNA cleavage/ligation active site of topoisomerase IIα and inhibit the catalytic activity of the enzyme by interfering with the DNA strand passage step.
Collapse
|
6
|
Targeting polyamine metabolism for cancer therapy and prevention. Biochem J 2017; 473:2937-53. [PMID: 27679855 DOI: 10.1042/bcj20160383] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 06/10/2016] [Indexed: 12/22/2022]
Abstract
The chemically simple, biologically complex eukaryotic polyamines, spermidine and spermine, are positively charged alkylamines involved in many crucial cellular processes. Along with their diamine precursor putrescine, their normally high intracellular concentrations require fine attenuation by multiple regulatory mechanisms to keep these essential molecules within strict physiologic ranges. Since the metabolism of and requirement for polyamines are frequently dysregulated in neoplastic disease, the metabolic pathway and functions of polyamines provide rational drug targets; however, these targets have been difficult to exploit for chemotherapy. It is the goal of this article to review the latest findings in the field that demonstrate the potential utility of targeting the metabolism and function of polyamines as strategies for both chemotherapy and, possibly more importantly, chemoprevention.
Collapse
|
7
|
Bombarde O, Larminat F, Gomez D, Frit P, Racca C, Gomes B, Guilbaud N, Calsou P. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks. Mol Cancer Ther 2017; 16:2166-2177. [PMID: 28611105 DOI: 10.1158/1535-7163.mct-16-0767] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 04/18/2017] [Accepted: 05/24/2017] [Indexed: 11/16/2022]
Abstract
Poisons of topoisomerase II (TOP2) kill cancer cells by preventing religation of intermediate DNA breaks during the enzymatic process and thus by accumulating enzyme-drug-DNA complexes called TOP2 cleavage-complex (TOP2cc). F14512 is a highly cytotoxic polyamine-vectorized TOP2 inhibitor derived from etoposide and currently in clinical trials. It was shown in vitro that F14512 has acquired DNA-binding properties and that the stability of TOP2cc was strongly increased. Paradoxically, at equitoxic concentrations in cells, F14512 induced less DNA breaks than etoposide. Here, we directly compared etoposide and F14512 for their rates of TOP2cc production and resolution in human cells. We report that targeting of TOP2α and not TOP2β impacts cell killing by F14512, contrary to etoposide that kills cells through targeting both isoforms. Then, we show that despite being more cytotoxic, F14512 is less efficient than etoposide at producing TOP2α cleavage-complex (TOP2αcc) in cells. Finally, we report that compared with TOP2αcc mediated by etoposide, those generated by F14512 persist longer in the genome, are not dependent on TDP2 for cleaning break ends from TOP2α, are channeled to a larger extent to resection-based repair processes relying on CtIP and BRCA1 and promote RAD51 recruitment to damaged chromatin. In addition to the addressing of F14512 to the polyamine transport system, the properties uncovered here would be particularly valuable for a therapeutic usage of this new anticancer compound. More generally, the concept of increasing drug cytotoxicity by switching the repair mode of the induced DNA lesions via addition of a DNA-binding moiety deserves further developments. Mol Cancer Ther; 16(10); 2166-77. ©2017 AACR.
Collapse
Affiliation(s)
- Oriane Bombarde
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Florence Larminat
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Dennis Gomez
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Philippe Frit
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Carine Racca
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Bruno Gomes
- Pierre Fabre Research Institute, CRDPF, Toulouse Cedex, France
| | | | - Patrick Calsou
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France. .,Equipe labellisée Ligue Nationale Contre le Cancer 2013
| |
Collapse
|
8
|
Boyé P, Serres F, Marescaux L, Hordeaux J, Bouchaert E, Gomes B, Tierny D. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma. PLoS One 2017; 12:e0177486. [PMID: 28505195 PMCID: PMC5432161 DOI: 10.1371/journal.pone.0177486] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Accepted: 04/27/2017] [Indexed: 12/31/2022] Open
Abstract
Comparative oncology has shown that naturally occurring canine cancers are of valuable and translatable interest for the understanding of human cancer biology and the characterization of new therapies. This work was part of a comparative oncology project assessing a new, clinical-stage topoisomerase II inhibitor and comparing it with etoposide in dogs with spontaneous lymphoma with the objective to translate findings from dogs to humans. Etoposide is a topoisomerase II inhibitor widely used in various humans' solid and hematopoietic cancer, but little data is available concerning its potential antitumor efficacy in dogs. Etoposide phosphate is a water-soluble prodrug of etoposide which is expected to be better tolerated in dogs. The objectives of this study were to assess the safety, the tolerability and the efficacy of intravenous etoposide phosphate in dogs with multicentric lymphoma. Seven dose levels were evaluated in a traditional 3+3 phase I design. Twenty-seven owned-dogs with high-grade multicentric lymphoma were enrolled and treated with three cycles of etoposide phosphate IV injections every 2 weeks. Adverse effects were graded according to the Veterinary Cooperative Oncology Group criteria. A complete end-staging was realized 45 days after inclusion. The maximal tolerated dose was 300 mg/m2. At this dose level, the overall response rate was 83.3% (n = 6, 3 PR and 2 CR). Only a moderate reversible gastrointestinal toxicity, no severe myelotoxicity and no hypersensitivity reaction were reported at this dose level. Beyond the characterization of etoposide clinical efficacy in dogs, this study underlined the clinical and therapeutic homologies between dog and human lymphomas.
Collapse
Affiliation(s)
- Pierre Boyé
- Oncovet-Clinical-Research (OCR), SIRIC ONCOLille, Parc Eurasanté, Loos, France
- Oncovet, SIRIC ONCOLille, Villeneuve d’Ascq, France
| | - François Serres
- Oncovet-Clinical-Research (OCR), SIRIC ONCOLille, Parc Eurasanté, Loos, France
- Oncovet, SIRIC ONCOLille, Villeneuve d’Ascq, France
| | | | - Juliette Hordeaux
- Oncovet-Clinical-Research (OCR), SIRIC ONCOLille, Parc Eurasanté, Loos, France
| | - Emmanuel Bouchaert
- Oncovet-Clinical-Research (OCR), SIRIC ONCOLille, Parc Eurasanté, Loos, France
| | - Bruno Gomes
- Institut de Recherche Pierre Fabre, Toulouse, France
| | - Dominique Tierny
- Oncovet-Clinical-Research (OCR), SIRIC ONCOLille, Parc Eurasanté, Loos, France
- Oncovet, SIRIC ONCOLille, Villeneuve d’Ascq, France
| |
Collapse
|
9
|
Corcé V, Gouin SG, Renaud S, Gaboriau F, Deniaud D. Recent advances in cancer treatment by iron chelators. Bioorg Med Chem Lett 2015; 26:251-256. [PMID: 26684852 DOI: 10.1016/j.bmcl.2015.11.094] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Revised: 11/12/2015] [Accepted: 11/25/2015] [Indexed: 01/19/2023]
Abstract
The development of new therapeutic alternatives for cancers is a major public health priority. Among the more promising approaches, the iron depletion strategy based on metal chelation in the tumoral environment has been particularly studied in recent decades. After a short description of the importance of iron for cancer cell proliferation, we will review the different iron chelators developed as potential chemotherapeutics. Finally, the recent efforts to vectorize the chelating agents specifically in the microtumoral environment will be discussed in detail.
Collapse
Affiliation(s)
- Vincent Corcé
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Sébastien G Gouin
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Stéphanie Renaud
- INSERM, UMR 991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes 1, 35043 Rennes, France
| | - François Gaboriau
- INSERM, UMR 991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes 1, 35043 Rennes, France
| | - David Deniaud
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| |
Collapse
|
10
|
Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. Cancer Lett 2015; 370:10-8. [PMID: 26404751 DOI: 10.1016/j.canlet.2015.09.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Revised: 09/06/2015] [Accepted: 09/07/2015] [Indexed: 12/12/2022]
Abstract
Epithelial ovarian cancer is the fourth cause of death among cancer-bearing women and frequently associated with carboplatin resistance, underlining the need for more efficient and targeted therapies. F14512 is an epipodophylotoxin-core linked to a spermine chain which enters cells via the polyamine transport system (PTS). Here, we investigate this novel concept of vectorization in ovarian cancer. We compared the effects of etoposide and F14512 on a panel of five carboplatin-sensitive or resistant ovarian cancer models. We assessed the incorporation of F17073, a spermine-linked fluorescent probe, in these cells and in 18 clinical samples. We then showed that F14512 exhibits a high anti-proliferative and pro-apoptotic activity, particularly in cells with high levels of F17073 incorporation. Consistently, F14512 significantly inhibited tumor growth compared to etoposide, in a cisplatin-resistant A2780R subcutaneous model, at a dose of 1.25 mg/kg. In addition, ex vivo analysis indicated that 15 out of 18 patients presented a higher F17073 incorporation into tumor cells compared to normal cells. Overall, our data suggest that F14512, a targeted drug with a potent anti-tumor efficacy, constitutes a potential new therapy for highly PTS-positive and platinum-resistant ovarian cancer-bearing patients.
Collapse
Affiliation(s)
- Benoît Thibault
- EA4553, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France
| | - Emily Clement
- EA4553, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France
| | - Grégoire Zorza
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Samuel Meignan
- Centre Oscar Lambret, INSERM, 3 rue Frédéric Combemale, 9000 Lille, France
| | - Jean-Pierre Delord
- EA4553, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France
| | - Bettina Couderc
- EA4553, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France.
| | - Christian Bailly
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Fabrice Narducci
- Centre Oscar Lambret, INSERM, 3 rue Frédéric Combemale, 9000 Lille, France
| | - Isabelle Vandenberghe
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Anna Kruczynski
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Nicolas Guilbaud
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Pierre Ferré
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| | - Jean-Philippe Annereau
- Centre de recherche et développement Pierre Fabre, 2 avenue Hubert Curien, 31562 Toulouse, France
| |
Collapse
|
11
|
Renaud S, Corcé V, Cannie I, Ropert M, Lepage S, Loréal O, Deniaud D, Gaboriau F. Quilamine HQ1-44, an iron chelator vectorized toward tumor cells by the polyamine transport system, inhibits HCT116 tumor growth without adverse effect. Biochem Pharmacol 2015; 96:179-89. [DOI: 10.1016/j.bcp.2015.06.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Accepted: 06/01/2015] [Indexed: 11/25/2022]
|
12
|
Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, Pétain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferré P, Guilbaud N, Gomes B. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clin Cancer Res 2015; 21:5314-23. [PMID: 26169968 DOI: 10.1158/1078-0432.ccr-14-3174] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 07/04/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. F14512 is currently in a phase I/II clinical trial in patients with acute myeloid leukemia. The aim of this study was to investigate F14512 potential in a new clinical indication. Because of the many similarities between human and dog lymphomas, we sought to determine the tolerance, efficacy, pharmacokinetic/pharmacodynamic (PK/PD) relationship of F14512 in this indication, and potential biomarkers that could be translated into human trials. EXPERIMENTAL DESIGN Twenty-three dogs with stage III-IV naturally occurring lymphomas were enrolled in the phase I dose-escalation trial, which consisted of three cycles of F14512 i.v. injections. Endpoints included safety and therapeutic efficacy. Serial blood samples and tumor biopsies were obtained for PK/PD and biomarker studies. RESULTS Five dose levels were evaluated to determine the recommended dose. F14512 was well tolerated, with the expected dose-dependent hematologic toxicity. F14512 induced an early decrease of tumoral lymph node cells, and a high response rate of 91% (21/23) with 10 complete responses, 11 partial responses, 1 stable disease, and 1 progressive disease. Phosphorylation of histone H2AX was studied as a potential PD biomarker of F14512. CONCLUSIONS This trial demonstrated that F14512 can be safely administered to dogs with lymphoma resulting in strong therapeutic efficacy. Additional evaluation of F14512 is needed to compare its efficacy with standards of care in dogs, and to translate biomarker and efficacy findings into clinical trials in humans.
Collapse
Affiliation(s)
- Dominique Tierny
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - François Serres
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Zacharie Segaoula
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France. Inserm, UMR-S1172, Jean Pierre Aubert Research Centre, Lille, France. Université de Lille, Lille, France
| | - Ingrid Bemelmans
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Emmanuel Bouchaert
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Aurélie Pétain
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Viviane Brel
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France
| | - Stéphane Couffin
- Institut de Recherche Pierre Fabre, Pharmacokinetics, Bel Air de Campans, Castres, France
| | - Thierry Marchal
- UPSP 2011-03-101, Interaction Cellules Environnement, Campus Vétérinaire de VetAgro-Sup, Marcy l'Etoile, France
| | - Laurent Nguyen
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Xavier Thuru
- Inserm, UMR-S1172, Jean Pierre Aubert Research Centre, Lille, France. Université de Lille, Lille, France
| | - Pierre Ferré
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Nicolas Guilbaud
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France
| | - Bruno Gomes
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France.
| |
Collapse
|
13
|
Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S. Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. Invest New Drugs 2014; 32:883-92. [PMID: 25008900 DOI: 10.1007/s10637-014-0132-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Accepted: 06/29/2014] [Indexed: 10/25/2022]
Abstract
The poor prognosis of children with high-grade glioma (HGG) and high-risk neuroblastoma, despite multidisciplinary therapeutic approaches, demands new treatments for these indications. F14512 is a topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells via the Polyamine Transport System (PTS) and increases topoisomerase II poisoning. Here, F14512 was evaluated in pediatric HGG and neuroblastoma cell lines. PTS activity and specificity were evaluated using a fluorescent spermine-coupled probe. The cytotoxicity of F14512, alone or in combination with ionizing radiation and chemotherapeutic agents, was investigated in vitro. The antitumor activity of F14512 was assessed in vivo using a liver-metastatic model of neuroblastoma. An active PTS was evidenced in all tested cell lines, providing a specific and rapid transfer of spermine-coupled compounds into cell nuclei. Competition experiments confirmed the essential role of PTS in the cell uptake and cytotoxicity of F14512. This cytotoxicity appeared greater in neuroblastoma cells compared with HGG cells but appeared independent of PTS activity levels. In vivo evaluation confirmed a marked and prolonged antitumoral effect in neuroblastoma cells. The combinations of F14512 with cisplatin and carboplatin were often found to be synergistic, and we demonstrated the significant radiosensitizing potential of F14512 in the MYCN-amplified Kelly cell line. Thus, F14512 appears more effective than etoposide in pediatric tumor cell lines, with greater efficacy in neuroblastoma cells compared with HGG cells. The synergistic effects observed with platinum compounds and the radiosensitizing effect could lead to a clinical development of the drug in pediatric oncology.
Collapse
Affiliation(s)
- Pierre Leblond
- Pediatric oncology unit, Centre Oscar Lambret, Lille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Spermidine/spermine N1-acetyltransferase activity associates with white blood cell count in myeloid leukemias. Exp Hematol 2014; 42:574-80. [DOI: 10.1016/j.exphem.2014.02.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Revised: 01/20/2014] [Accepted: 02/10/2014] [Indexed: 01/09/2023]
|
15
|
Schmidt F, George P, Sapi J. Chemical biology: contribution to molecular therapeutic innovation--a new role for chemistry? Report from the thematic symposium organized by the SCT (French Medicinal Chemistry Society), November 26th, 2013. ACS Chem Biol 2014; 9:849-52. [PMID: 24742389 DOI: 10.1021/cb500173s] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Frédéric Schmidt
- SCT Communication Officer; Institut Curie, Research Center, CNRS UMR3666, INSERM U1143, 26 rue d’Ulm, F-75248 Paris, France
| | - Pascal George
- SCT President,
Independent Scientific
Expert and Adviser
| | - Janos Sapi
- SCT Vice-President; UMR CNRS 7312, Université de Reims-Champagne-Ardenne, 51 rue Cognacq-Jay, F- 51096 Reims cedex, France
| |
Collapse
|
16
|
Ketron AC, Osheroff N. Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2014; 13:19-35. [PMID: 24678287 PMCID: PMC3963363 DOI: 10.1007/s11101-013-9291-7] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Phytochemicals are a rich source of anticancer drugs and chemopreventive agents. Several of these chemicals appear to exert at least some of their effects through interactions with topoisomerase II, an essential enzyme that regulates DNA supercoiling and removes knots and tangles from the genome. Topoisomerase II-active phytochemicals function by stabilizing covalent protein-cleaved DNA complexes that are intermediates in the catalytic cycle of the enzyme. As a result, these compounds convert topoisomerase II to a cellular toxin that fragments the genome. Because of their mode of action, they are referred to as topoisomerase II poisons as opposed to catalytic inhibitors. The first sections of this article discuss DNA topology, the catalytic cycle of topoisomerase II, and the two mechanisms (interfacial vs. covalent) by which different classes of topoisomerase II poisons alter enzyme activity. Subsequent sections discuss the effects of several phytochemicals on the type II enzyme, including demethyl-epipodophyllotoxins (semisynthetic anticancer drugs) as well as flavones, flavonols, isoflavones, catechins, isothiocyanates, and curcumin (dietary chemopreventive agents). Finally, the leukemogenic potential of topoisomerase II-targeted phytochemicals is described.
Collapse
Affiliation(s)
- Adam C. Ketron
- Department of Biochemistry and the Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 USA
| | - Neil Osheroff
- Departments of Biochemistry and Medicine (Hematology/Oncology) and the Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 USA
| |
Collapse
|
17
|
Corcé V, Renaud S, Cannie I, Julienne K, Gouin SG, Loréal O, Gaboriau F, Deniaud D. Synthesis and Biological Properties of Quilamines II, New Iron Chelators with Antiproliferative Activities. Bioconjug Chem 2014; 25:320-34. [DOI: 10.1021/bc4004734] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Vincent Corcé
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité,
Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR
des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
- INSERM,
UMR 991,
CHRU Pontchaillou, 35033 Rennes, France
- Université de Rennes 1, 35043 Rennes, France
| | - Stéphanie Renaud
- INSERM,
UMR 991,
CHRU Pontchaillou, 35033 Rennes, France
- Université de Rennes 1, 35043 Rennes, France
| | - Isabelle Cannie
- INSERM,
UMR 991,
CHRU Pontchaillou, 35033 Rennes, France
- Université de Rennes 1, 35043 Rennes, France
| | - Karine Julienne
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité,
Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR
des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Sébastien G. Gouin
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité,
Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR
des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Olivier Loréal
- INSERM,
UMR 991,
CHRU Pontchaillou, 35033 Rennes, France
- Université de Rennes 1, 35043 Rennes, France
| | - François Gaboriau
- INSERM,
UMR 991,
CHRU Pontchaillou, 35033 Rennes, France
- Université de Rennes 1, 35043 Rennes, France
| | - David Deniaud
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité,
Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR
des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| |
Collapse
|
18
|
The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. Oral Oncol 2013; 50:113-9. [PMID: 24290982 DOI: 10.1016/j.oraloncology.2013.11.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Revised: 10/28/2013] [Accepted: 11/08/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide. The treatment of advanced stages HNSCC is based on surgical treatment combined with radiotherapy and chemotherapy or concomitant chemo-radiotherapy. However, the 5-year survival remains poor for advanced stages HNSCC and the development of new targeted therapies is eagerly awaited. F14512 combines an epipodophyllotoxin core-targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. This spermine moiety facilitates selective uptake by tumor cells via the Polyamine Transport System (PTS) and reinforces topoisomerase II poisoning. Here we report the evaluation of F14512 toward HNSCC. MATERIALS AND METHODS Four cell lines representative of head and neck cancer localizations were used: Fadu (pharynx), SQ20B (larynx), CAL33 and CAL27 (base of the tongue). PTS activity and specificity were evaluated by confocal microscopy and flow cytometry using the fluorescent probe F17073 which contains the same spermine moiety as F14512. Cytotoxicity, alone or in association with standard chemotherapeutic agents (cisplatin, 5FU), and radio-sensitizing effects were investigated using MTS and clonogenic assays, respectively. F14512 efficiency and PTS activity were also measured under hypoxic conditions (1% O2). RESULTS In all 4 tested HNSCC lines, an active PTS was evidenced providing a specific and rapid transfer of spermine-coupled compounds into cell nuclei. Interestingly, F14512 presents a 1.6-11-fold higher cytotoxic effect than the reference compound etoposide (lacking the spermine chain). It appears also more cytotoxic than 5FU and cisplatin in all cell lines. Competition experiments with spermine confirmed the essential role of the PTS in the cell uptake and cytotoxicity of F14512. Hypoxia had almost no impact on the drug cytotoxicity. The combination of F14512 with cisplatin, but not 5FU, was found to be synergistic and, for the first time, we demonstrated the significant radio-sensitizing potential of F14512. CONCLUSION The spermine moiety of F14512 confers a targeted effect and a much better efficacy than etoposide in HNSCC lines. The synergistic effect observed in association with cisplatin and radiotherapy augurs well for the potential development of F14512 in HNSCC.
Collapse
|
19
|
Muth A, Kamel J, Kaur N, Shicora AC, Ayene IS, Gilmour SK, Phanstiel O. Development of Polyamine Transport Ligands with Improved Metabolic Stability and Selectivity against Specific Human Cancers. J Med Chem 2013; 56:5819-28. [DOI: 10.1021/jm400496a] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Aaron Muth
- Department of Medical Education, University of Central Florida College of Medicine,
12722 Research Parkway, Orlando, Florida 32826-3227, United States
- Department of Chemistry, 4000
Central Florida Boulevard, University of Central Florida, Orlando, Florida 32816, United States
| | - Joseph Kamel
- Department of Medical Education, University of Central Florida College of Medicine,
12722 Research Parkway, Orlando, Florida 32826-3227, United States
| | - Navneet Kaur
- Department of Chemistry, 4000
Central Florida Boulevard, University of Central Florida, Orlando, Florida 32816, United States
| | - Allyson C. Shicora
- Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood,
Pennsylvania 19096, United States
| | - Iraimoudi S. Ayene
- Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood,
Pennsylvania 19096, United States
| | - Susan K. Gilmour
- Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood,
Pennsylvania 19096, United States
| | - Otto Phanstiel
- Department of Medical Education, University of Central Florida College of Medicine,
12722 Research Parkway, Orlando, Florida 32826-3227, United States
| |
Collapse
|
20
|
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. Leukemia 2013; 27:2139-48. [PMID: 23568148 DOI: 10.1038/leu.2013.108] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 03/28/2013] [Accepted: 04/04/2013] [Indexed: 12/31/2022]
Abstract
Chemotherapy remains mainly used for the treatment of acute myeloid leukemia (AML). However, in the past 3 decades limited progress has been achieved in improving the long-term disease-free survival. Therefore the development of more effective drugs for AML represents a high level of priority. F14512 combines an epipodophyllotoxin core targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine moiety facilitates F14512 selective uptake by tumour cells via the polyamine transport system, a machinery overactivated in cancer cells. F14512 has been characterized as a potent drug candidate and is currently in Phase I clinical trials. Here, we demonstrated marked survival benefit and therapeutic efficacy of F14512 treatments in a series of human AML models, established either from AML cell lines or from patient AML samples. Furthermore, we reported in vitro synergistic anti-leukemic effects of F14512 in combination with cytosine arabinoside (Ara-C), doxorubicin, gemcitabine, bortezomib or SAHA. In vivo combination of suboptimal doses of F14512 with Ara-C also resulted in enhanced anti-leukemic activity. We further showed that F14512 triggered both senescence and apoptosis in vivo in primary AML models, but not autophagy. Overall, these results support the clinical development in onco-hematology of this novel promising drug candidate.
Collapse
|
21
|
Kornienko A, Mathieu V, Rastogi SK, Lefranc F, Kiss R. Therapeutic Agents Triggering Nonapoptotic Cancer Cell Death. J Med Chem 2013; 56:4823-39. [DOI: 10.1021/jm400136m] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University—San Marcos, San Marcos, Texas 78666,
United States
| | - Véronique Mathieu
- Laboratoire
de Toxicologie, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Campus de la Plaine, CP205/1,
Boulevard du Triomphe, Brussels, Belgium
| | - Shiva K. Rastogi
- Department of Chemistry and Biochemistry, Texas State University—San Marcos, San Marcos, Texas 78666,
United States
| | - Florence Lefranc
- Service de Neurochirurgie, Hôpital Erasme, ULB, 808 Route de Lennik, 1070 Brussels, Belgium
| | - Robert Kiss
- Laboratoire
de Toxicologie, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Campus de la Plaine, CP205/1,
Boulevard du Triomphe, Brussels, Belgium
| |
Collapse
|
22
|
Corcé V, Morin E, Guihéneuf S, Renault E, Renaud S, Cannie I, Tripier R, Lima LMP, Julienne K, Gouin SG, Loréal O, Deniaud D, Gaboriau F. Polyaminoquinoline Iron Chelators for Vectorization of Antiproliferative Agents: Design, Synthesis, and Validation. Bioconjug Chem 2012; 23:1952-68. [DOI: 10.1021/bc300324c] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Vincent Corcé
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
- INSERM, UMR991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes1,
35043 Rennes, France
| | - Emmanuelle Morin
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - Solène Guihéneuf
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - Eric Renault
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - Stéphanie Renaud
- INSERM, UMR991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes1,
35043 Rennes, France
| | - Isabelle Cannie
- INSERM, UMR991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes1,
35043 Rennes, France
| | - Raphaël Tripier
- CNRS, UMR 6521, Université de Brest, Laboratoire
de Chimie, Electrochimie
Moléculaires et Chimie Analytique, 6 Avenue Victor Le Gorgeu,
29200 Brest, France
| | - Luís M. P. Lima
- CNRS, UMR 6521, Université de Brest, Laboratoire
de Chimie, Electrochimie
Moléculaires et Chimie Analytique, 6 Avenue Victor Le Gorgeu,
29200 Brest, France
| | - Karine Julienne
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - Sébastien G. Gouin
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - Olivier Loréal
- INSERM, UMR991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes1,
35043 Rennes, France
| | - David Deniaud
- LUNAM Université, CEISAM,
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques,
2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France
| | - François Gaboriau
- INSERM, UMR991, CHRU Pontchaillou, 35033 Rennes, France; Université de Rennes1,
35043 Rennes, France
| |
Collapse
|
23
|
Bailly C. Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Chem Rev 2012; 112:3611-40. [PMID: 22397403 DOI: 10.1021/cr200325f] [Citation(s) in RCA: 213] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Christian Bailly
- Centre de Recherche et Développement, Institut de Recherche Pierre Fabre, Toulouse, France.
| |
Collapse
|
24
|
Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. Biochem Pharmacol 2011; 82:1843-52. [DOI: 10.1016/j.bcp.2011.08.028] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2011] [Revised: 08/30/2011] [Accepted: 08/31/2011] [Indexed: 11/24/2022]
|
25
|
Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P, Bailly C, Marchetti P. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II. Apoptosis 2011; 17:364-76. [DOI: 10.1007/s10495-011-0681-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
26
|
Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A. 99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation. Eur J Nucl Med Mol Imaging 2011; 38:1832-41. [PMID: 21660624 DOI: 10.1007/s00259-011-1857-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2011] [Accepted: 05/26/2011] [Indexed: 11/28/2022]
Abstract
PURPOSE F14512 exploiting the polyamine transport system (PTS) for tumour cell delivery has been described as a potent antitumour agent. The optimal use of this compound will require a probe to identify tumour cells expressing a highly active PTS that might be more sensitive to the treatment. The aim of this study was to design and characterize a scintigraphic probe to evaluate its uptake in cancer cells expressing the PTS. METHODS Three polyamines coupled to a hydrazinonicotinamide (HYNIC) moiety were synthesized and labelled with 99mTc. Their radiochemical purity was determined by HPLC. The plasma stability of the 99mTc-HYNIC-spermine probe and its capacity to accumulate into PTS-active cells were also evaluated. In vitro internalization was tested using murine melanoma B16/F10 cells and human lung carcinoma A549 cells. Biodistribution was determined in healthy mice and tumour uptake was studied in B16/F10 tumour-bearing mice. A HL-60-Luc human leukaemia model was used to confront single photon emission computed tomography (SPECT) images obtained with the 99mTc-labelled probe with those obtained by bioluminescence. RESULTS The 99mTc-HYNIC-spermine probe was selected for its capacity to accumulate into PTS-active cells and its stability in plasma. In vitro studies demonstrated that the probe was internalized in the cells via the PTS. In vivo measurements indicated a tumour to muscle scintigraphic ratio of 7.9±2.8. The combined bioluminescence and scintigraphic analyses with the leukaemia model demonstrated that the spermine conjugate accumulates into the tumour cells. CONCLUSION The 99mTc-HYNIC-spermine scintigraphic probe is potentially useful to characterize the PTS activity of tumours. Additional work is needed to determine if this novel conjugate may be useful to analyse the PTS status of patients with solid tumours.
Collapse
Affiliation(s)
- Sabrina Pesnel
- Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France,
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 2011; 50:3240-9. [PMID: 21413765 DOI: 10.1021/bi200094z] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
F14512 is a novel etoposide derivative that contains a spermine in place of the C4 glycosidic moiety. The drug was designed to exploit the polyamine transport system that is upregulated in some cancers. However, a preliminary study suggests that it is also a more efficacious topoisomerase II poison than etoposide [Barret et al. (2008) Cancer Res. 68, 9845-9853]. Therefore, we undertook a more complete study of the actions of F14512 against human type II topoisomerases. As determined by saturation transfer difference (1)H NMR spectroscopy, contacts between F14512 and human topoisomerase IIα in the binary enzyme-drug complex are similar to those of etoposide. Although the spermine of F14512 does not interact with the enzyme, it converts the drug to a DNA binder [Barret et al. (2008)]. Consequently, the influence of the C4 spermine on drug activity was assessed. F14512 is a highly active topoisomerase II poison and stimulates DNA cleavage mediated by human topoisomerase IIα or topoisomerase IIβ. The drug is more potent and efficacious than etoposide or TOP-53, an etoposide derivative that contains a C4 aminoalkyl group that strengthens drug-enzyme binding. Unlike the other drugs, F14512 maintains robust activity in the absence of ATP. The enhanced activity of F14512 correlates with a tighter binding and an increased stability of the ternary topoisomerase II-drug-DNA complex. The spermine-drug core linkage is critical for these attributes. These findings demonstrate the utility of a C4 DNA binding group and provide a rational basis for the development of novel and more active etoposide-based topoisomerase II poisons.
Collapse
Affiliation(s)
- Amanda C Gentry
- Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States
| | | | | | | | | | | |
Collapse
|
28
|
Tomasi S, Renault J, Martin B, Duhieu S, Cerec V, Le Roch M, Uriac P, Delcros JG. Targeting the Polyamine Transport System with Benzazepine- and Azepine-Polyamine Conjugates. J Med Chem 2010; 53:7647-63. [DOI: 10.1021/jm1007648] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Sophie Tomasi
- Produits Naturels−Synthèses−Chimie Médicinale, Sciences Chimiques de Rennes, CNRS UMR 6226, Faculté de Pharmacie, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Jacques Renault
- Produits Naturels−Synthèses−Chimie Médicinale, Sciences Chimiques de Rennes, CNRS UMR 6226, Faculté de Pharmacie, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Bénédicte Martin
- Groupe de Recherche en Thérapeutique Anticancéreuse, Faculté de Médecine, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Stephane Duhieu
- Groupe de Recherche en Thérapeutique Anticancéreuse, Faculté de Médecine, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Virginie Cerec
- Groupe de Recherche en Thérapeutique Anticancéreuse, Faculté de Médecine, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Myriam Le Roch
- Produits Naturels−Synthèses−Chimie Médicinale, Sciences Chimiques de Rennes, CNRS UMR 6226, Faculté de Pharmacie, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Philippe Uriac
- Produits Naturels−Synthèses−Chimie Médicinale, Sciences Chimiques de Rennes, CNRS UMR 6226, Faculté de Pharmacie, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| | - Jean-Guy Delcros
- Groupe de Recherche en Thérapeutique Anticancéreuse, Faculté de Médecine, Université Rennes 1, Université Européenne de Bretagne, Rennes Cedex, France
| |
Collapse
|